- NCIt
- C7185
Loading cancer entity…
Loading cancer entity…
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (130)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05334238 | Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | unknown | Phase 3 | 174 | Ruijin HospitalOTHER | 1 | Apr 19, 2022 | clinicaltrials |
| NCT02313389 | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma(BLOCAGE-01) | unknown | Phase 3 | 428 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05054426 | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL(NHL-011) | unknown | Phase 3 | 488 | Peking Union Medical College HospitalOTHER | 1 | Sep 23, 2021 | clinicaltrials |
| NCT02085655 | PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma | unknown | Phase 3 | 264 | Huiqiang HuangOTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT03733327 | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | unknown | Phase 2 / Phase 3 | 20 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 7, 2018 | clinicaltrials |
| NCT00725231 | Immunotherapy in Peripheral T Cell Lymphoma - the Role of Alemtuzumab in Addition to Dose Dense CHOP(A-CHOP-14) | unknown | Phase 3 | 274 | University of GöttingenOTHER | 1 | May 7, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Apr 19, 2022source: clinicaltrials